Guanfacine Tablet, Extended Release
Product Images NDC 63629-8161

6 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 63629-8161). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-structure (Spl Structure)

Spl-structure (Spl Structure)
Chemical structure of Guanfacine Hydrochloride (HCl) showing a chlorinated aromatic ring connected to a guanidine group. This structural formula represents the active ingredient Guanfacine in its hydrochloride salt form.*
FDA Label Image

Spl-fig-1 (Spl Fig 1)

Spl-fig-1 (Spl Fig 1)
A plasma concentration versus time graph comparing guanfacine extended-release tablets 1 mg QD and Tenex 1 mg QD. The y-axis shows guanfacine plasma concentration in ng/mL, ranging from 0 to 4.0, and the x-axis shows time in hours up to 24. The graph illustrates different plasma concentration profiles for both formulations over a 24-hour period.*
FDA Label Image

Spl-fig-2 (Spl Fig 2)

Spl-fig-2 (Spl Fig 2)
A pharmacokinetic chart depicting fold change and 90% confidence intervals for Cmax and AUC values of Guanfacine under various conditions. The chart compares changes relative to reference when administered with CYP3A4 inhibitors (Ketoconazole), CYP3A4 inducers (Rifampin), oral methylphenidate, and lisdexamfetamine dimesylate. The x-axis represents change relative to reference from 0 to 5.*
FDA Label Image

Spl-fig-3 (Spl Fig 3)

Spl-fig-3 (Spl Fig 3)
A chart showing pharmacokinetic (PK) parameters Cmax and AUC for interacting drugs Oral Methylphenidate and Lisdexamfetamine Dimesylate. The graph displays fold change and 90% confidence intervals relative to reference, with values centered around 1.0 indicating no significant change in drug exposure.*
FDA Label Image

Spl-fig-4 (Spl Fig 4)

Spl-fig-4 (Spl Fig 4)
A line graph depicting treatment failure percentage over time in days for two groups: Placebo and SPD503. The x-axis represents time to treatment failure in days, ranging from 0 to about 200 days, and the y-axis represents treatment failure percentage from 0% to 100%. The graph shows a higher treatment failure rate over time in the placebo group compared to SPD503, with SPD503 having a consistently lower failure percentage throughout the study period.*
FDA Label Image

Label (Lbl636298161)

Label (Lbl636298161)
Label for Guanfacine ER 1 mg extended-release tablet by Bryant Ranch Prepack. The white round tablet is identified as RJ70. The label indicates storage at 20°-25°C (68°-77°F) and includes a caution to keep all drugs out of reach of children. The package contains 30 tablets and displays the NDC 63629-8161 and lot number 1523487.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.